The impact you'll make | The Big Give Christmas Challenge 2023

NICE approves life-saving treatment for children with infantile lysosomal acid lipase deficiency

SMC do not recommend pegunigalsidase alfa (Elfabrio®) for adult Fabry patients

NICE approves life-changing medication for treatment of alpha mannosidosis

NICE approves its first ERT for treating Fabry disease

Bob's rare disease road trip

TOGETHER WE CAN TRANSFORM LIVES

TOGETHER WE CAN TRANSFORM LIVES

NICE unfortunately leans towards a ‘no’ for the treatment of early onset LAL D (Wolman disease)

Robert's story | MPS Awareness Week 2023

MPS Society Strategy 2023-2026

Impact report 2022

BBC documentary highlights the importance of Newborn Screening for early diagnosis

Celebrating 40 years

NICE leans towards a no for the treatment of Alpha Mannosidosis

Footsteps Dance School raises funds in honour of Isaac Turner

MPS Society celebrates after receiving £10,000 in National Lottery funding

Takeda to discontinue their TAK-609 clinical trial

NICE approves life-changing medication for treating MPS IVA Morquio

NICE final guidance approves life-changing gene therapy for treating MLD

NICE update on the re-evaluation for the treatment of MPS IVA (Morquio A)

AVROBIO ends its gene therapy trial for Fabry disease

NICE leans towards a no for the treatment of MPS IVA (Morquio A)

Will changes to NICE processes work for rare diseases?

MPS Society’s Group CEO elected to the ABPI’s new Patient Advisory Council

COVID-19 vaccination for children and young people aged 12-17 years

NICE unfortunately leans towards a no for the treatment of Metachromatic Leukodystrophy (MLD).

MPS 2021 International Symposium

Vimizim update from NICE for MPS IVA (Morquio)

New COHERE study for MPS II patients

MPS Society's chance to win £1,000

What's new for Sophie?

We welcome Mandy who has started a brand new role at the MPS Society

Conference 2021 Announcement

National Lottery Community Fund award £195K to build connections and reduce feelings of isolation

MPS Society welcomes new UK Rare Diseases Framework

Treatment for Metachromatic Leukodystrophy (MLD) approved by the European Commission

Latest information for clinically extremely vulnerable adults and children

Kelly Mills' charity appeal for MPS Society on Radio 4

AVROBIO announce collaborative research agreement with Manchester university for MPS II gene therapy

REGENXBIO announces expansion of gene therapy programme for the treatment of MPS II

Tune in to Kelly Mills' charity appeal for MPS Society on Radio 4 this month

Ross Kemp's Living With Dementia series visits a family affected by Sanfilippo

Impact report 2019/20

Brain disease treatment shows promising signs

NHS England and shielding (updated 24 June 2020)

Paediatric advice on clinical support and homecare (updated 26 March)

Changes to our service as a result of COVID-19

MPS Society response to Budget announcement

Advice for patients, parents and guardians on inherited metabolic disease and Coronavirus (COVID-19)